Overview

Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507

Status:
Not yet recruiting

Trial end date:
2022-12-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to determine the efficacy and safety of DWJ1506 and DWJ1507 in the patients with dyslipidemia.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Criteria

Inclusion Criteria:

1. Adults aged 19 years or over

2. Patients with LDL-C levels ≤ 250 mg/dL, TG < 500 mg/dL

3. Subjects who voluntarily decided to participate and provided written consent after
being told of the objectives, method, and effects of this study

Exclusion Criteria:

1. Severe congestive hear failure

2. Current active liver disease

3. The use of prohibiterd concomitant therapies

4. Severe gastrointestinal diseases: active ulcer, gastrointestinal or rectal bleeding,
active inflammatory bowel syndrome, biliary duct obstruction, active gastritis that is
not controlled by medication, etc.

6.Women who were of childbearing potential without contraception, pregnant, or
breastfeeding